Table 1.

Characteristics of study group

	Matched patient group		Other LTx patients
	BOS	Non-BOS	BOS	Non-BOS
Total number	7	7	3	40
BOS grade
I	0	n.a.	0	n.a.
II	3	n.a.	0	n.a.
III	4	n.a.	3	n.a.
Mean follow-up	38(69–9)	39(65–32)	21(17–33)	17(76–6)
Mean age	51(24–61)	50(22–61)	39(23–58)	41(17–64)
Primary disease
CF	1(14%)	1(14%)	2(67%)	16(40%)
Emphysema	4(57%)	4(57%)	0(0%)	14(35%)
Fibrotic disease	2(29%)	2(29%)	1(33%)	10(25%)
Infections
CMV	0(0%)	1(14%)	0(0%)	2(5%)
EBV	0(0%)	0(0%)	0(0%)	1(2·5%)
Pseudomonas	3(42%)	1(14%)	2(67%)	18(45%)

Characteristics of 14 matched patients for longitudinal study, and the 43 other lung transplant (LTx) patients included in this study. A division is made between the patients who developed bronchiolitis obliterans syndrome (BOS) and the patients who have not developed BOS. Three patients had a cytomegalovirus (CMV) infection; two patients were CMV-negative and received lungs from a CMV-positive donor, one CMV-positive patient received lungs from a CMV-negative donor. One patient had an Epstein–Barr virus (EBV) reactivation. CF, cystic fibrosis; n.a., not available.